Table 2. Multivariable model and adjusted odds ratio of variables considered for pCR of ER+ breast cancer patients.
| Variables | Odds ratio | 95% CI | P value |
|---|---|---|---|
| Age | |||
| ≤40y vs. >40y | 1.44 | 0.72 - 2.85 | 0.30 |
| Grade | |||
| Grade III vs.I | 3.00 | 0.94 - 9.58 | 0.06 |
| Grade II vs.I | 2.09 | 0.78 - 5.60 | 0.14 |
| TNM stage | |||
| Stage II∼III vs. I | 3.24 | 1.30 - 8.05 | 0.01 |
| NPI | |||
| <3.4 vs. >5.4 | 18.82 | 4.19 - 84.63 | <0.001 |
| 3.4∼5.4 vs. >5.4 | 3.32 | 1.23 - 8.92 | 0.02 |
| Tumor size | |||
| ≤5cm vs. >5cm | 3.40 | 1.11 - 10.44 | 0.03 |
| LN status | |||
| Negative vs. Positive | 1.28 | 0.61 - 2.66 | 0.52 |
| PR | |||
| Negative vs. Positive | 1.08 | 0.52 - 2.25 | 0.84 |
| Her2 | |||
| Negative vs. Positive | 1.03 | 0.40 - 2.65 | 0.95 |
| Ki67 | |||
| >14% vs. ≤14% | 1.28 | 0.66 - 2.48 | 0.46 |
| IHC4 score | |||
| Q1 vs.Q3 | 5.49 | 1.04 - 28.87 | 0.04 |
| Q2 vs.Q3 | 3.20 | 0.89 - 11.56 | 0.08 |
Abbreviations: NPI, Nottingham Prognosis Index; LN, lymph node; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; IHC4, A combined four immunohistochemical marker score.